Butyrate-producing gut bacteria (null)

Butyrate-producing gut bacteria comprise a functional group of anaerobic microorganisms, mainly belonging to Firmicutes (notably Clostridium clusters IV and XIVa, including genera such as *Faecalibacterium*, *Roseburia*, *Eubacterium*, *Subdoligranulum*, *Anaerostipes*, and *Coprococcus*), which generate butyrate as a key end-product of carbohydrate fermentation[1][2][3][4]. Butyrate serves as a primary energy source for colonocytes, enhances epithelial barrier integrity, exerts anti-inflammatory effects by limiting pro-inflammatory cytokines, secretes antimicrobial substances, and inhibits oncogenic signaling pathways in the colon[1]. The abundance and function of butyrate producers are strongly associated with prevention of inflammatory diseases and maintenance of gut homeostasis; depletion is linked to IBD, colorectal cancer, and metabolic disorders[1][3][4]. These bacteria are not a single therapeutic target like receptors or enzymes, but are a group of organisms relevant for probiotic development, predictive biomarkers, and nutritional interventions in diseases involving dysbiosis[2][3]. Butyrate producers is not a canonical drug target (like a receptor, enzyme, or protein) but a *community/ecological grouping* of beneficial bacteria. The concept is *important for therapeutic nutrition, microbiome-directed interventions, and biomarker research* but does not map to a singular molecular entity or target for small molecule drugs[1][2][3][4].

Other names

Butyrate-producing bacteriabutyrogenic bacteriabutyrate producers

Fermentation of dietary carbohydrates to produce butyrate via specific metabolic pathways (primarily the butyryl-CoA:acetate CoA-transferase pathway, also butyrate kinase pathway)[1][2][3] Modulation of metabolic and immunological signaling by release of butyrate in the gut